AzTrials
AzTrials

Wounds and InjuriesRABBITNCT03522636

Rapid Administration of Blood by HEMS in Trauma

An observational study of Wounds and Injuries and Acute Coagulopathy, run by Zdravotnicka Zachranna Sluzba Kralovehradeckeho Kraje at 2 sites in Czechia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Trauma is a leading cause of death among people younger than 44 years. Five million people worldwide die from trauma annually. Uncontrolled haemorrhage causing traumatic-haemorrhagic shock (THS) is the leading cause of potentially preventable deaths from severe trauma. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Wounds and Injuries, Acute Coagulopathy, Trauma
How many people
100 participants
Where
2 sitesCzechia
Study dates
1 Jun 2018to Dec 2019
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All injured patients treated by a physician-staffed HEMS team will be eligible for inclusion. Authorized on-scene HEMS physicians will be responsible to make decision to administer prehospital blood if one or more of the anatomical and/or physiological inclusion criteria are met. Prehospital transfusion will always be considered as a life-saving intervention.

Who may be able to join

  • Physiological indications
  • Hypotension with absent radial pulse
  • Hypotension with systolic arterial blood pressure < 100 mmHg
  • Anatomical indications
  • Penetrating thoracic and/or abdominal injuries with signs of severe bleeding
  • Injuries to neck, groins and/or axilla with signs of severe bleeding
Show all 18Show fewer
  • Clinical signs of intraabdominal bleeding
  • Unstable chest wall
  • Unstable pelvis
  • Closed and/or open fractures of two or more long bones (femur, tibia, humerus)
  • Open fracture of at least one femur type OIII
  • Open fracture of pelvis
  • Partial and/or total amputation limb injury above knee and/or elbow with severe external blood loss
  • Mechanism of injury (supporting indications)
  • Human torso entrapped in the vehicle with need for extrication (thorax, abdomen, pelvis)
  • Fall from height of > 6 metres (on scene verification needed)
  • Human torso (thorax, abdomen, pelvis) over-driven by a motor vehicle
  • Human torso (thorax, abdomen, pelvis) compressed by a heavy object or animal

Who cannot join

  • Absolute contraindications
  • Traumatic cardiac arrest (TCA) from a blunt injury before decision to administer blood products. Any ROSC after resuscitation of TCA is not a contraindication.
  • Relative contraindications
  • Traumatic brain injury (TBI) caused by direct force towards head region (e.g. gunshot) without signs of injury to other systems or body areas
  • Age under 15 years.
  • Any other admitting hospital than trauma center of the University Hospital Hradec Kralove

Trial locations and contacts

2 sites in 1 country.

Anatolij Truhlar, MD PhD FERC contact

00420606816818

truhlaran@zzskhk.cz

Jaromir Koci, MD PhD FACS contact

00420728898467‬

jaromir.koci@fnhk.cz

Czechia2 sites, 2 recruiting
  • University Hospital Hradec Kralove

    Hradec Králové, 50005

    Jaromir Koci, MD PhD FACS, 00420728898467‬, jaromir.koci@fnhk.cz

    Jana Berkova, MD, 00420606337353‬, jana.berkova@fnhk.cz

    Not yet recruiting
  • Zdravotnicka zachranna sluzba Kralovehradeckeho kraje

    Hradec Králové, 50012

    Anatolij Truhlar, MD PhD FERC, 00420606816818, truhlaran@zzskhk.cz

    Marek Dvorak, MD, dvorakma@zzskhk.cz

    Recruiting

Other trials in Czechia

About this study

Official title: Effect of Pre-hospital Blood Transfusion on Early Outcomes in Trauma Patients Transported by Physician-staffed HEMS (Helicopter Emergency Medical Service)

Trauma is a leading cause of death among people younger than 44 years. Five million people worldwide die from trauma annually. Uncontrolled haemorrhage causing traumatic-haemorrhagic shock (THS) is the leading cause of potentially preventable deaths from severe trauma. Uncorrected hypervolaemia and prolonged shock cause severe tissue hypoperfusion, vital organ ischemia and subsequently acidosis. In up to one third of trauma patients, laboratory findings suggest traumatic induced coagulopathy, which is further triggered by loss or dilution of coagulation factors. These patients have a significantly increased morbidity and mortality compared to patients with similar injury patterns without coagulopathy. Minimizing the time to surgical control of haemorrhage is key in order to improve outcome. However, immediate and goal directed volume and coagulation resuscitation including use of blood transfusion is crucial to enable survival until definitive hospital care. The primary objective of this study will be to evaluate feasibility of prehospital administration of 1 unit of human plasma and 1 unit of red blood cells, and explore association of early prehospital transfusion with early outcomes in patients presenting with THS, severe bleeding or peri-arrest state who are matching indication criteria and are transported by Helicopter Emergency Medical Service. Results of clinical examinations and laboratory variables in a group of patients receiving prehospital transfusion will be compared to matched population of patients treated before blood has been available on board. Secondary aim of the study is to detect any potential logistical and/or organisational adverse effects, incl. cost-effectiveness, in a regional trauma system with prehospital times (time of injury to trauma centre) ranging from 45 to 75 minutes.

Read the detailed description

Background and rationale of the project Trauma is a leading cause of death among people younger than 44 years. Uncontrolled haemorrhage causing traumatic-haemorrhagic shock (THS) is the leading cause of potentially preventable deaths from severe trauma. Uncorrected hypervolaemia and prolonged shock cause severe tissue hypoperfusion, vital organ ischemia and subsequently acidosis. Shock, acidosis and hypothermia are recognized drivers of anti-coagulant and fibrinolytic pathways. In up to one third of trauma patients, laboratory findings suggest traumatic induced coagulopathy, which is further triggered by loss or dilution of coagulation factors. These patients have a significantly increased morbidity and mortality compared to patients with similar injury patterns without coagulopathy. Minimizing the time to surgical control of haemorrhage is key in order to improve outcome. However, immediate and goal directed volume and coagulation resuscitation including use of blood product transfusion is crucial to enable survival until definitive hospital care.

Role of HEMS in a trauma system. Helicopter Emergency Medical Services (HEMS) can rapidly deliver advanced medical care and speed up patient transport to designated trauma centres. In the Czech Republic, HEMS covers 76.5% of the area and 99.4% of the population of the Czech Republic within 20 minutes since the emergency call is received via Emergency Medical Dispatch Centre (EMDC). HEMS Hradec Kralove is one of the well-recognized systems in the country. Its catchment area is 1.1 million inhabitants living in the Hradec Kralove and Pardubice regions. Trauma patients include 100-120 multiple trauma injuries and 50-60 isolated traumatic brain injuries (TBI) annually. In 2017, there were 95.9% primary flights (to the scene of accident), of which 81.9% take-offs were decided by EMDC dispatchers immediately after receiving an emergency call. Management of patients in THS requires early identification of the bleeding source, use of effective techniques to stop compressible haemorrhage, support of clot formation and minimisation of on-going blood loss in non-compressible haemorrhage, judicious fluid resuscitation with monitoring of effect, and a pre-alert system for damage control resuscitation or surgery at the receiving hospital. HEMS teams must be skilled to recognise and treat massive bleeding and acute traumatic coagulopathy in the pre-hospital environment.

Diagnostics of THS. Haemorrhage leads to a fall in systemic filling pressure and venous return. The resulting decrease in cardiac minute volume, and therefore in oxygen and nutrient supply, sets off an endogenous stress response aiming to maintain perfusion pressure. Thus, blood pressure and heart rate must be interpreted with caution, and cardiac output might have dropped to some 60% until blood pressure will start to decrease. Although a systolic blood pressure <90 mmHg is the typically considered as the leading symptom of hypovolemic shock, clinical assessment of trauma patients comprises on-going and repeated evaluation of the mental status, capillary filling time, clinical appearance, changes in heart rate, and mechanism of injury. Current literature suggests that the combined evaluation of heart rate, SABP, Glasgow Coma Scale (GCS) and the ability to maintain a patent airway increases the predictability for advanced in-hospital interventions up to four times. This is of particular importance for an in-hospital blood transfusion request policy. Suitable triggers for preparation for massive transfusion are suspicion or evidence of active haemorrhage, incl. trauma triage criteria, systolic arterial blood pressure (SABP) < 90 mmHg, failure to respond to a fluid bolus, heart rate > 120/min, and penetrating injuries. Accordingly, physical examination on scene should focus on injury patterns known to cause haemorrhage such as penetrating trauma, pelvic or femoral fractures and blunt abdominal trauma.

Prehospital treatment of THS. The up-to-date concept of initial trauma care is called damage control resuscitation, which comprises hypotensive resuscitation, haemostatic resuscitation and damage control surgery. Control of haemorrhage is crucial in order to interrupt the vicious circle of blood loss, hypervolaemia, hypoperfusion, acidosis and coagulopathy, finally resulting in therapy refractory shock and death. Basic techniques like direct compression, pressure dressings, tourniquets, traction devices and pelvic splints are used routinely in obvious or suspicious bleeding. In life threatening haemorrhagic shock, fluid resuscitation is still the main stem therapy. The primary and ultimate goal of pre-hospital fluid resuscitation is to prevent hypovolemic cardiac arrest and to minimize organ damage caused by prolonged or uncorrected hypotension causing organ ischemia. For this reason permissive hypotension should only be applied in the first hour after the insult. There are extensive side effects of fluid resuscitation in uncontrolled bleeding patients. Inappropriate or over-infusion has been shown to harm and to worsen outcome. Hypotensive resuscitation is a temporary strategy for management of patients with uncontrolled blood loss until the source of bleeding is controlled. Fluid resuscitation should be spared or postponed in patients with uncontrolled haemorrhage, normal mental status and SABP > 90 mmHg. Fluids should be titrated in uncontrolled bleeding patients without head trauma to a target SABP around 90 mmHg. However, it is noteworthy that the concept of hypotensive resuscitation must be tailored and adjusted to the patients need. In patients with severe traumatic brain injury higher SABP must be achieved with higher amounts of fluids and very seldom use of vasopressor drugs when necessary. There is an on-going debate which fluids and what amounts should be considered optimal for haemorrhagic shock management. Colloids did not show to improve outcome when compared with crystalloids. The same is true for hyperosmolar solutions. Compared to the United Kingdom, Scandinavia and other highly developed countries, there are no prehospital blood products currently available in Central, Southern and Eastern Europe, partially because of high logistic and material demands, risk of wasting, high expenses, and unproven benefit of prehospital use of red blood cells without plasma.

Co-operation between HEMS and a trauma centre. The regional trauma system in the Hradec Kralove Region has been gradually developed during last couple of years. One of its main advantages is excellent long-term co-operation between EMDC, HEMS, and receiving trauma centre, incl. quality management. There are different triage tools used to help to outline patient routes to trauma centres. These latter can include immediate need for blood or life saving surgery. In Hradec Kralove, it was for the first time in the Czech Republic, when a new concept of trauma triage was implemented and improved on-scene triage. The triage criteria were adopted from the American College of Surgeons (ACS) and include: mechanism of injury (e.g. fall from height > 6 m, person trapped in a vehicle), anatomical and physiological criteria, and selected special considerations (e.g. age, comorbidities). Its specificity is 8-10% and sensitivity 95-97%. The same triage system was later implemented into all other prehospital systems, integrated into the nation-wide recommendations of the Ministry of Health (Trauma Care in the Czech Republic) and Guidelines of the Czech Society for Emergency and Disaster Medicine ČLS JEP. Use of pre-hospital triage can predict risk of THS and need for specialized trauma care.

Prehospital blood transfusion. Haemostatic resuscitation is the very early use of blood products as primary resuscitation fluid to prevent exsanguination by trauma-induced coagulopathy. The recommended ratio of packed red cells, fresh frozen plasma and platelets is 1:1:1. In a few locations around the world, physician led HEMS teams provide advanced medical interventions such as thoracotomy, resuscitative endovascular balloon occlusion of aorta (REBOA), and blood product (BP) transfusion which traditionally occurred in the highly specialized hospital centres. Administration of BPs in a helicopter has been studied in specific cohorts including either longer transport times to definitive treatment facility, high prevalence of penetrating thorax and epigastrium injuries, or war injuries with restricted medical care. The potential role of packed red blood cells is yet to be identified, although many HEMS systems already demonstrated feasibility. Recent systematic review searching bibliographic databases to July 2015 did not identify any prospective comparative or randomized studies on prehopsital use of BPs. A single study showed improved survival in the first 24 hours, but vast majority of studies provided very low quality of evidence. None of these studies was performed on a cohort of patients similar to the population treated in our setting: blunt injuries and short prehospital times. Transfusion reactions were rare, suggesting the short-term safety of prehospital BP administration equal to those occurring at emergency departments. Current practice at the HEMS Hradec Kralove is to prealert the admitting facility and request blood products from the scene. These are available after helicopter arrival at hospital. It was calculated that availability of BPs on board would result in earlier BP transfusion for at least 20-30 minutes compared to current situation.

Hypothesis. Given evidence in support of massive transfusion protocol in hospitals, the investigators hypothesize that early prehospital BP transfusion will be associated with lower risk of THS and coagulopathy on admission to the trauma centre, and during 24 hours after admission. Lower requirements for BP transfusion during 24 hours after admission, improved 24-hour mortality, and outcome on discharge from hospital are also expected.

Statistical analysis. Conditional logistic regression and mixed-effects linear regression will be used to determine the association of early administration of BP transfusion with outcome variables. Patients receiving BP transfusion are supposed to be more severely injured with a higher risk of mortality. Because of this, we cannot compare their outcome data to those of patients without prehospital BP transfusions, but with a retrospective cohort of patients who had received massive transfusion protocol already requested by HEMS from the scene during the period of previous 12/24 months before implementation of BP transfusion into HEMS. To prevent selection bias, the propensity score model will be developed to predict the likelihood of receiving BP transfusion based on several prehospital variables to allow appropriate matching of treated and control patients based on this probability of receiving BP transfusion. Covariates in the propensity score model will include age, SABP, heart rate, crystalloid volume before HEMS arrival (if given by a ground ambulance team), crystalloid volume during HEMS transport, type of injury (blunt vs. penetrating), prehospital time and distance to hospital. Covariates for 24-hour survival will include at least sex, Injury Severity Score (ISS), SABP, heart rate and Glasgow Coma Score (GCS) at admission, INR, rotational thromboelastometry (ROTEM) parameters (e.g. clotting time, alfa-angle), intensive care unit admission, days of mechanical ventilation, and need for surgery. Similar covariates will be used for THS and trauma induced coagulopathy indicators. Subgroup analysis will be performed for patients with traumatic cardiac arrest.

Keywords
Prehospital transfusion, Trauma, Trauma induced coagulopathy
Medical subject headings
Wounds and Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT03522636
Study groupRoleWhat they receive
TreatmentPrehospital blood products resuscitation up to 2 units of blood products as follows: 1 unit of packed human plasma and 1 unit of packed red blood cells
Historic controlNo prehospital blood products available

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Units of blood products used

    Transfusion units of red blood cells, plasma and platelets

    Measured: Time of injury to 24 hours

Secondary outcomes (10)
  1. Prehospital time

    Prehospital time (time of injury to arrival at trauma centre)

    Measured: Time of injury to 24 hours

  2. Volume of pre-hospital fluids

    Volume of fluids (crystalloids) given until hospital admission

    Measured: Time of injury to 24 hours

  3. Blood pressure on admission to trauma centre

    Systolic and diastolic blood pressure on admission to trauma centre

    Measured: Time of injury to 24 hours

  4. Trauma-induced coagulopathy

    NR > 1.5 and coagulation variables measured viscoelastically by rotational thromboelastometry (ROTEM)

    Measured: Time of injury to 24 hours

  5. Lactate concentration

    Venous lactate concentration

    Measured: Admission to 24 hours

  6. ICU stay

    Days of stay at intensive care unit

    Measured: Admission to discharge from acute care hospital or 1 month

  7. Days of mechanical ventillation

    Days of mechanical ventillation

    Measured: Time of injury to discharge from acute care hospital or 1 month

  8. Sepsis-related organ failure assessment (SOFA) score

    Sepsis-related organ failure assessment (SOFA) score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems assisting in estimating the risk of morbidity and mortality

    Measured: Admission to discharge from acute care hospital or 1 month

  9. Complications

    Transfusion related reactions, logistical, and organisational complications

    Measured: Time of injury to discharge from acute care hospital or 1 month

  10. 24 hour and 30 day mortality

    Trauma-related mortality between time of injury and up to discharge from acute care hospital or 1 month

    Measured: 24 hours and 1 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 May 2018
  2. Study start1 Jun 2018
  3. Primary completion31 May 2019 (estimated)
  4. Study completionDec 2019 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03522636
Sponsor's protocol ID
20180001
Acronym
RABBIT
Status last verified
Jun 2018
First submitted
31 Mar 2018
Last updated
6 Jun 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Wounds and Injuries and Acute Coagulopathy, run by Zdravotnicka Zachranna Sluzba Kralovehradeckeho Kraje at 2 sites in Czechia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 18 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Anatolij Truhlar, MD PhD FERC (00420606816818, truhlaran@zzskhk.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Units of blood products used (time frame: Time of injury to 24 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in